SLC5A2 and diabetes mellitus: In patients with diabetes mellitus, treatment with SGLT2 inhibitors has been shown to be associated with cardiometabolic benefits such as weight loss, [20, 21] BP reduction [22] and improvements in lipid profiles [23, 24].